Residual Cardiovascular Risk in Diabetic Patients: The Role of Fibrate Statin Combination

Angelos Liontos, Moses S. Elisaf, *Theodosios D. Filippatos

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
*Correspondence to filtheo@gmail.com

Disclosure: No potential conflict of interest.
Received: 02.05.14 Accepted: 31.07.14
Citation: EMJ Diabet. 2014;2:83-87.

Abstract

Patients with Type 2 diabetes mellitus (T2DM) have increased cardiovascular disease (CVD) risk. The use of statins significantly reduces the rate of CVD events but many T2DM patients, especially those with mixed dyslipidaemia (MD), have residual CVD risk. The use of fibrates, which improve triglyceride and high-density lipoprotein cholesterol levels, is beneficial for the treatment of patients with MD. Evidence from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid study showed a possible beneficial effect on CVD events of the addition of fenofibrate (FF) to statin treatment in patients with T2DM and atherogenic MD. Furthermore, FF has been associated with slowing of the progression of early diabetic retinopathy. The combination of statin with a fibrate may improve the residual CVD risk and microvascular complications of patients with T2DM. However, trials specifically designed to assess the effects of fibrate-statin combination on cardiovascular outcomes in patients with T2DM are missing.

Download (PDF, 83KB)

Comments are closed.